Monitoring Src status after dasatinib treatment in HER2+ breast cancer with ⁸⁹ Zr-trastuzumab PET imaging.

Autor: McKnight BN; Department of Oncology, Karmanos Cancer Institute, 4100 John R Street, Detroit, MI, 48201, USA., Viola-Villegas NT; Department of Oncology, Karmanos Cancer Institute, 4100 John R Street, Detroit, MI, 48201, USA. villegan@karmanos.org.

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2018 Oct 25; Vol. 20 (1), pp. 130. Date of Electronic Publication: 2018 Oct 25.

⁸⁹ Zr-ImmunoPET companion diagnostics and their impact in clinical drug development.

Autor: McKnight BN; Cancer Biology, Wayne State University School of Medicine, Detroit, Michigan, USA., Viola-Villegas NT; Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan, USA.

Publikováno v: Journal of labelled compounds & radiopharmaceuticals [J Labelled Comp Radiopharm] 2018 Jul; Vol. 61 (9), pp. 727-738. Date of Electronic Publication: 2018 Mar 12.

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Autor: Bosch A; Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA., Li Z; Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA., Bergamaschi A; Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, 524 Burrill Hall, Urbana, IL 61801, USA., Ellis H; Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA., Toska E; Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA., Prat A; Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain. Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Hospital Clinic Barcelona, C/Rosselló 149-153, Barcelona 08035, Spain., Tao JJ; Massachusetts General Hospital Cancer Center and Harvard Medical School, 425 13th Street, Charlestown, MA 02129, USA., Spratt DE; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Viola-Villegas NT; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Castel P; Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA., Minuesa G; Molecular Pharmacology and Chemistry Program and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Morse N; Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA., Rodón J; Department of Medical Oncology, VHIO, Barcelona 08035, Spain. Universitat Autònoma de Barcelona, Plaza Cívica, Campus UAB, 08193 Bellaterra, Spain., Ibrahim Y; Experimental Therapeutics Group, VHIO, Barcelona 08035, Spain., Cortes J; Department of Medical Oncology, VHIO, Barcelona 08035, Spain., Perez-Garcia J; Department of Medical Oncology, VHIO, Barcelona 08035, Spain., Galvan P; Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain., Grueso J; Experimental Therapeutics Group, VHIO, Barcelona 08035, Spain., Guzman M; Experimental Therapeutics Group, VHIO, Barcelona 08035, Spain., Katzenellenbogen JA; Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA., Kharas M; Molecular Pharmacology and Chemistry Program and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Lewis JS; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Molecular Pharmacology and Chemistry Program and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Dickler M; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Serra V; Experimental Therapeutics Group, VHIO, Barcelona 08035, Spain., Rosen N; Molecular Pharmacology and Chemistry Program and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Chandarlapaty S; Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA. chandars@mskcc.org scaltrim@mskcc.org baselgaj@mskcc.org., Scaltriti M; Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. chandars@mskcc.org scaltrim@mskcc.org baselgaj@mskcc.org., Baselga J; Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA. chandars@mskcc.org scaltrim@mskcc.org baselgaj@mskcc.org.

Publikováno v: Science translational medicine [Sci Transl Med] 2015 Apr 15; Vol. 7 (283), pp. 283ra51.

Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer.

Autor: Viola-Villegas NT; Program in Molecular Pharmacology and Chemistry, andDepartments of Radiology., Carlin SD; Program in Molecular Pharmacology and Chemistry, andDepartments of Radiology., Ackerstaff E; Medical Physics., Sevak KK; Departments of Radiology., Divilov V; Departments of Radiology., Serganova I; Neurology, and., Kruchevsky N; Medical Physics., Anderson M; Department of Physics, University of Rhode Island, Kingston, RI 02881; and., Blasberg RG; Program in Molecular Pharmacology and Chemistry, andDepartments of Radiology,Neurology, and., Andreev OA; Department of Physics, University of Rhode Island, Kingston, RI 02881; and., Engelman DM; Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520 donald.engelman@yale.edu lewisj2@mskcc.org., Koutcher JA; Program in Molecular Pharmacology and Chemistry, andDepartments of Radiology,Medical Physics,Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065;, Reshetnyak YK; Department of Physics, University of Rhode Island, Kingston, RI 02881; and., Lewis JS; Program in Molecular Pharmacology and Chemistry, andDepartments of Radiology, donald.engelman@yale.edu lewisj2@mskcc.org.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2014 May 20; Vol. 111 (20), pp. 7254-9. Date of Electronic Publication: 2014 May 01.

(18)F-labeled-bioorthogonal liposomes for in vivo targeting.

Autor: Emmetiere F; Department of Radiology, ‡Department of Medical Physics, §Molecular Imaging and Therapy Service, Department of Radiology, and ∥Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center , New York, New York, 10065, United States., Irwin C, Viola-Villegas NT, Longo V, Cheal SM, Zanzonico P, Pillarsetty N, Weber WA, Lewis JS, Reiner T

Publikováno v: Bioconjugate chemistry [Bioconjug Chem] 2013 Nov 20; Vol. 24 (11), pp. 1784-9. Date of Electronic Publication: 2013 Nov 07.